ClinicalTrials.Veeva

Menu

Precision Cancer Therapy in Rare Cancers (MATRIX-Rare)

University of Oslo (UIO) logo

University of Oslo (UIO)

Status and phase

Enrolling
Phase 2

Conditions

Rare Malignant Neoplasm

Treatments

Drug: Trametinib
Drug: Imatinib
Drug: Dabrafenib

Study type

Interventional

Funder types

Other

Identifiers

NCT06119789
MATRIX-Rare

Details and patient eligibility

About

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers.

In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Full description

All patients will have the tumour cells diagnosed with a large genepanel, analyzing more than 500 genes on DNA / RNA level. Patients will be treated based on the molecular characteristics of the tumor cells.

Enrollment

96 estimated patients

Sex

All

Ages

16 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ECOG 0-2,
  • identified biomarker,
  • reasonable biochemistry

Exclusion criteria

  • ECOG 3-5
  • serious other diseases

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

96 participants in 1 patient group

treatment according to genetic alterations
Experimental group
Description:
treatment according to genetic alterations
Treatment:
Drug: Dabrafenib
Drug: Trametinib
Drug: Imatinib

Trial contacts and locations

1

Loading...

Central trial contact

Kathinka Slørdahl, MD PhD; Åslaug Helland, MD PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems